Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >
"Preeclampsia is a very exciting indication, and PSTI has the potential to completely change how we treat this insidious disease." (6/4/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert More >
Ross Silver has been advising, researching and investing in public companies across all industries throughout his career. Prior to founding Vista Partners LLC in 2005, Silver served as a research analyst for a San Francisco-based hedge fund. From 2000 to 2003, Silver served as a research associate covering consumer discretionary and consumer staple companies at Dresdner RCM (now Allianz). Prior to joining Dresdner RCM, Silver was a member of CIBC's Technology, Media, and Telecom Investment Banking group, where he assisted with equity and debt offerings. Silver holds a bachelor's degree in business economics from the University of California, Santa Barbara. He has served as a consultant for government agencies including the National Institutes of Health (NIH). He holds a Series 65 Securities license.
Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy (12/6/12) Many components go into building a successful biotech company, but excellent management is a keystone. Combine good management with an innovative product or service, and investors can possibly unlock big multiples over their original investments. So says Principal Analyst and Fund Manager Ross Silver, co-founder of Vista Partners. In this interview with The Life Sciences Report, Silver brings obscure micro-cap ideas to life and discusses why they may have mammoth potential.
"OCLS has an alternative to antibiotics, and it won't cause resistant bacteria to evolve. That's what's so exciting." (12/6/12) Oculus Innovative Sciences Inc. - The Life Sciences Report Interview with Ross Silver More >
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >